Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.

09/29/2026, 5:35 AM • The Motley Fool

Teva Releases Q3 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.

09/23/2026, 4:45 PM • GlobeNewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.

09/23/2026, 4:45 PM • GlobeNewswire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.

09/18/2026, 4:32 PM • GlobeNewswire

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva announced real-world data demonstrating that UZEDY (risperidone) extended-release injectable suspension shows superior treatment continuity compared to other long-acting injectables in schizophrenia patients and oral antipsychotics in bipolar I disorder. The data revealed UZEDY reduced emergency room visits and hospitalizations, delivering over $1,000 per patient per month in direct cost savings and 40% lower emergency department visit rates versus paliperidone palmitate once-monthly.

09/18/2026, 4:31 PM • GlobeNewswire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva presented post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine formulation for schizophrenia treatment. Results showed over 56% of participants achieved stabilization, 21% achieved remission after 6+ months, and only 4% of stabilized patients relapsed. Data also demonstrated feasible switching strategies from oral or short-acting olanzapine formulations while maintaining therapeutic ranges. FDA approval is anticipated in Q4 2026.

09/18/2026, 4:30 PM • GlobeNewswire

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

09/07/2026, 1:00 PM • GlobeNewswire

Teva Announces Launch of Offering of Senior Notes

Teva Pharmaceutical announced its intention to issue EUR and USD-denominated senior notes through special purpose finance subsidiaries. The company plans to use net proceeds to redeem certain existing notes, including 6.750% notes due 2028, 7.875% and 7.375% sustainability-linked notes due 2029, and portions of 4.750% and 4.375% notes. The offering is subject to market conditions and is not conditioned on the redemptions.

09/07/2026, 3:53 AM • GlobeNewswire

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.

08/26/2026, 1:00 PM • GlobeNewswire

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Michael R. Hayden, a director at Ionis Pharmaceuticals, purchased 20,000 shares worth $1.1 million on July 30-31, 2026, increasing his total holdings by 34%. The insider purchase signals confidence in the company's RNA-targeted therapy pipeline, which includes recently approved drugs like Tryngolza and upcoming treatments for Alexander disease and Angelman syndrome. Despite current net losses of $564.8 million, the company maintains $873.8 million in trailing twelve-month revenue and an $8.8 billion market valuation.

08/03/2026, 3:17 PM • The Motley Fool

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

07/09/2026, 12:12 PM • The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

07/06/2026, 1:09 PM • The Motley Fool

Teva Releases Q2 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd. announced the availability of its Q2 2026 Aide Memoire document to assist investors ahead of second quarter 2026 results, scheduled for release on July 29, 2026. The company also announced an upcoming conference call to discuss financial results. The article includes standard forward-looking statements and risk disclosures.

06/18/2026, 5:00 PM • GlobeNewswire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva Pharmaceutical has submitted a New Drug Application (NDA) to the FDA for ecopipam, a first-in-class dopamine D1 receptor antagonist for treating pediatric Tourette syndrome. The submission is supported by positive Phase 3 data published in JAMA Neurology, showing ecopipam significantly delayed time to relapse compared to placebo with a p-value of 0.008. If approved, ecopipam could be the first FDA-approved treatment for pediatric Tourette syndrome in over a decade.

06/18/2026, 4:57 PM • GlobeNewswire

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 5,222 shares for approximately $143,000 on June 8, 2026, reducing his holdings by 3.60%. While his remaining stake of 139,763 shares keeps his interests aligned with investors, the sale follows a pattern of regular dispositions over the past year. The company faces headwinds from an upcoming generic competition agreement with Teva Pharmaceuticals for its flagship drug Jelmyto starting September 2030, though growth in other products like Zusduri may offset losses.

06/14/2026, 11:14 AM • The Motley Fool